Serum Markers for the Prediction of Preeclampsia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Neurology and Neurophysiology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.4172/2155-9562.1000264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study.

  2014influential reference
• Pre-eclampsia part 1: current understanding of its pathophysiology

  2014cited by this paper
• Plasma Levels of Dimethylarginines in Preterm Very Low Birth Weight Neonates: Its Relation with Perinatal Factors and Short-Term Outcome

  2014influential reference
• Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

  2014cited by this paper
• Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia

  2014cited by this paper
• Biomarkers for the management of pre-eclampsia in pregnant women

  2013cited by this paper
• Role of nitric oxide, angiogenic growth factors and biochemical analysis in preeclampsia.

  2013cited by this paper
• Pathophysiology of hypertension in pre‐eclampsia: a lesson in integrative physiology

  2013cited by this paper
• Elevated maternal serum sP-selectin levels in preeclamptic pregnancies with and without intrauterine fetal growth restriction, but not in normotensive pregnancies complicated by isolated IUGR

  2013cited by this paper
• Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta.

  2013cited by this paper
• [Molecular mechanism of thrombopoietin signal pathways and its new effects].

  2013cited by this paper
• Pre-eclampsia and the risk of kidney disease.

  2013cited by this paper
• Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11–13 weeks in preeclampsia

  2012cited by this paper
• The role of endoglin in atherosclerosis.

  2012cited by this paper
• Molecular Mechanisms of Preeclampsia

  2012cited by this paper
• Maternal serum placental growth hormone at 11–13 weeks’ gestation in pregnancies delivering small for gestational age neonates

  2012cited by this paper
• PP13 and PAPP-A in the First and Second Trimesters: Predictive Factors for Preeclampsia?

  2012cited by this paper
• Maternal serum insulin‐like growth factor‐binding protein‐1 (IGFBP‐1) at 11–13 weeks in pre‐eclampsia

  2011cited by this paper
• Prediction of early, intermediate and late pre‐eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks

  2011cited by this paper
• Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease

  2011cited by this paper
• Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach

  2010cited by this paper
• Soluble forms of VEGF receptor‐1 and ‐2 promote vascular maturation via mural cell recruitment

  2010cited by this paper
• First‐trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction

  2010cited by this paper
• The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth

  2010cited by this paper
• Maternal serum insulin‐like growth factor‐I at 11–13 weeks in preeclampsia

  2010cited by this paper
• First-Trimester Prediction of Hypertensive Disorders in Pregnancy

  2009cited by this paper
• Novel Angiogenic Factors for Predicting Preeclampsia: sFlt-1, PlGF, and Soluble Endoglin~!2008-08-29~!2008-12-15~!2009-01-02~!

  2009cited by this paper
• Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy

  2009cited by this paper
• Preeclampsia: the role of angiogenic factors in its pathogenesis.

  2009cited by this paper
• The Role of Nitric Oxide Synthase Inhibition by Asymmetric Dimethylarginine in the Pathophysiology of Preeclampsia

  2009cited by this paper
• First trimester serum PAPP‐A and NGAL in the prediction of late‐onset pre‐eclampsia

  2009cited by this paper
• Asymmetric Dimethylarginine in the Maternal and Fetal Circulation in Preeclampsia

  2009cited by this paper
• First‐trimester maternal serum pregnancy‐associated plasma protein‐A and pre‐eclampsia

  2009cited by this paper
• The IGF Axis and Placental Function

  2008cited by this paper
• Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia

  2008cited by this paper
• Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion.

  2008cited by this paper
• First-trimester maternal serum PP13 in the risk assessment for preeclampsia.

  2008cited by this paper
• Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin?

  2008cited by this paper
• Screening for placental insufficiency in high-risk pregnancies: is earlier better?

  2008cited by this paper
• Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre‐eclampsia

  2008cited by this paper
• Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia.

  2008cited by this paper
• P-selectin in placenta and gestational myometrium: its measurements and hypothetical role in hemostasis of placental bed after labor.

  2008cited by this paper
• First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction

  2008cited by this paper
• Prediction of Maternal Predisposition to Preeclampsia

  2008cited by this paper
• Prediction of pre‐eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure

  2008cited by this paper
• Low levels of maternal serum PAPP‐A in the first trimester and the risk of pre‐eclampsia

  2008cited by this paper
• Contrasting effects of chronic hypoxia and nitric oxide synthase inhibition on circulating angiogenic factors in a rat model of growth restriction.

  2007cited by this paper
• Birth weight and subsequent risk of type 2 diabetes: a meta-analysis.

  2007cited by this paper
• Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset and Late-Onset Preeclampsia

  2007cited by this paper
• First‐trimester maternal serum PP‐13, PAPP‐A and second‐trimester uterine artery Doppler pulsatility index as markers of pre‐eclampsia

  2007cited by this paper
• First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction.

  2007cited by this paper
• Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

  2006cited by this paper
• Screening in early pregnancy for pre‐eclampsia using down syndrome quadruple test markers

  2006cited by this paper
• Maternal Serum and Amniotic Fluid Inhibin A Levels in Women who Subsequently Develop Severe Preeclampsia

  2006cited by this paper
• Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia.

  2006cited by this paper
• Soluble endoglin contributes to the pathogenesis of preeclampsia

  2006cited by this paper
• Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsia.

  2006cited by this paper
• Prediction of pre‐eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation

  2006cited by this paper
• Circulating Angiogenic Factors and the Risk of Preeclampsia

  2005cited by this paper
• Disruption of insulin-like growth factor-II imprinting during embryonic development rescues the dwarf phenotype of mice null for pregnancy-associated plasma protein-A.

  2005cited by this paper
• Shunting the intervillous space: new concepts in human uteroplacental vascularization.

  2005cited by this paper
• Stimulation of human trophoblast invasion by placental growth hormone.

  2005cited by this paper
• A novel approach to first‐trimester screening for early pre‐eclampsia combining serum PP‐13 and Doppler ultrasound

  2005cited by this paper
• Lack of thrombopoietin potentiation of platelet collagen activation in the first trimester is associated with preeclampsia.

  2005cited by this paper
• Make every mother and child count.

  2005cited by this paper
• Prediction of Preeclampsia

  2005cited by this paper
• Circulating Angiogenic Factors in Preeclampsia

  2005cited by this paper
• A sister's risk: family history as a predictor of preeclampsia.

  2005cited by this paper
• Hemodynamic and hemorheological profiles in women with proteinuric hypertension of pregnancy and in pregnant controls

  2004cited by this paper
• Markers of platelets activation, CD 62P and soluble P-selectin in healthy term neonates

  2004cited by this paper
• Asymmetrical Dimethylarginine: The Über Marker?

  2004cited by this paper
• A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth.

  2004cited by this paper
• Circulating angiogenic factors and preeclampsia.

  2004cited by this paper
• Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award.

  2004cited by this paper
• The measurement of maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein improves the early prediction of preeclampsia.

  2004cited by this paper
• P‐selectin in haemostasis

  2004cited by this paper
• Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women.

  2004cited by this paper
• Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia.

  2004cited by this paper
• Prediction of Preeclampsia: Can It Be Achieved?

  2004cited by this paper
• Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies.

  2004cited by this paper
• Maternal serum activin, inhibin, human chorionic gonadotrophin and α‐fetoprotein as second trimester predictors of pre‐eclampsia

  2003cited by this paper
• Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia.

  2003cited by this paper
• Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) could contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

  2003cited by this paper
• A new nonisotopic, highly sensitive assay for the measurement of human placental growth hormone: development and clinical implications.

  2003cited by this paper
• The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre‐eclampsia

  2003cited by this paper
• Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis

  2002cited by this paper
• Smoking before pregnancy and risk of gestational hypertension and preeclampsia.

  2002cited by this paper
• Human placental growth hormone--a review.

  2002cited by this paper
• Longitudinal study of serum placental GH in 455 normal pregnancies: correlation to gestational age, fetal gender, and weight.

  2002cited by this paper
• Thrombopoietin in Preterm Infants: Gestational Age-Dependent Response

  2002influential reference
• Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia

  2002cited by this paper
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002.

  2002cited by this paper
• Soluble P‐selectin levels during normal pregnancy: a longitudinal study

  2002cited by this paper
• Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

  2002cited by this paper
• Role of stress peptides during human pregnancy and labour.

  2002cited by this paper
• Placental Growth Hormone and Lactogen Production by Perifused Ovine Placental Explants: Regulation by Growth Hormone-Releasing Hormone and Glucose

  2002cited by this paper
• Erratum: Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia (Human Reproduction (2000) 15 (1640-1645))

  2001cited by this paper
• Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction.

  2001cited by this paper
• Plasma P‐selectin is elevated in the first trimester in women who subsequently develop pre‐eclampsia

  2001cited by this paper

• Quadruple Test Can Predict Hypertension in Pregnancy: The Excellent Center Hospital-based Study

  2024cites this paper
• The Yin and Yang Effect of the Apelinergic System in Oxidative Stress

  2023cites this paper
• Evaluation of maternal serum SERPINC1, E-selectin, P-selectin, RBP4 and PP13 levels in pregnancies complicated with preeclampsia

  2023cites this paper
• β-hCG levels in second trimester as a predictor of gestational hypertension and preeclampsia

  2022cites this paper
• Role of Maternal Serum Placental Protein 13 at 11-13 weeks of Pregnancy as a Predictor of Pre-eclampsia

  2021cites this paper
• Urinary Nephrin and Podocalyxin Levels as Predictors of Pre-eclampsia in High-Risk Pregnant Women.

  2021cites this paper
• Correlation between Apelin and Some Angiogenic Factors in the Pathogenesis of Preeclampsia: Apelin-13 as Novel Drug for Treating Preeclampsia and Its Physiological Effects on Placenta

  2021cites this paper
• Maternal serum Apelin 13 and APLN gene promoter variant -1860T > C in preeclampsia

  2021cites this paper
• Impact of Oxidative Stress on Maternal Serum Apelin 13 and Endothelial Nitric Oxide Synthase in Preeclampsia

  2020cites this paper
• Comparison of Maternal Serum Levels of Thrombopoietin among Pregnant Women with and without Preeclampsia

  2020influential citation
• Evaluation of urinary calcium to creatinine ratio as a predictor of preeclampsia

  2019cites this paper
• A Contemporary Review on Pregnancy Associated Disorders

  2018cites this paper
• Asymmetric Dimethyl Arginine and Cell Free Total DNA as Diagnostic Markers in Preeclampsia

  2017cites this paper
• Markers of obesity and growth in preeclamptic and normotensive pregnant women

  2017cites this paper
• Research & Reviews: Journal of Pharmacology and Toxicological Studies A Short Study on Phylogenetics

  2016cites this paper
• A Short Study on Phylogenetics

  2016cites this paper
• Research and Reviews: Journal of Botanical Sciences Advancement of Dendrogram

  2015cites this paper
• Research and Reviews: Journal of Pharmacognocy and Phytochemistry Physiology and its Importance

  2015cites this paper